Drugs / Aprepitant
Aprepitant
also known as
MK0869 · EMEND · aprepitant(emend) · Emend - aprepitant · MK-869 · APONVIE · APR · APREPITANT (MK-0869) · +6 more
Other / unclassified targets CYP3A4, TACR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed postoperative ventricular dysfunction 1 milestone | |||||
| Filed | US (FDA) | CINVANTI | postoperative ventricular dysfunction | 2021-11-18 | “today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant)” herontx.com ↗ “with the submission of the CINVANTI NDA” herontx.com ↗ |
| Approved Indication not stated 4 milestones | |||||
| Label expansions (2) | US (FDA) | CINVANTI | — | 2019-02-26 – 2019-10-21 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | EMEND | — | 2005-10-28 – 2015-08-28 | fda.gov ↗ |
| Approved | EU (EMA) | Emend | — | 2003-11-11 | europa.eu ↗ |
| Approved | US (FDA) | EMEND | — | 2003-03-26 | fda.gov ↗ |
Trials 126 · started per year
today
US approved 2003
EU approved 2003
5
6
1
4
7
5
6
5
11
9
9
6
2
6
7
3
4
3
4
4
2
2
1
8
2
4
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07845825 | Oct 2026 → May 2027 expected | atactic disorder, congenital contractures of the limbs and face, hypotonia, and developmental delay, neurodevelopmental disorder, neurological muscular channelopathy due to a genetic sodium channel defect | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT00314743 | Oct 2005 → Dec 2008 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT06931119 | May 2025 → May 2026 overdue | — | Rabin Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06226506 | Jan 2024 | — | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 1 | NCT03889366 | Mar → Apr 2019 | — | Nuformix Technologies Limited | Completed | No outcome recorded |
| Phase 1 | NCT03245918 | Aug → Dec 2017 | chemotherapy-induced toxicity | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 1 | NCT02058277 | May → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02154360 | May 2014 → Dec 2015 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT01527994 | Jan 2012 → Jun 2014 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT01111851 | Apr → Oct 2010 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01204723 | Aug 2009 → Jan 2012 | cannabis dependence, nicotine dependence, substance abuse | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT00818259 | Feb 2009 → Jan 2014 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00819039 | Jan 2009 → Mar 2013 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00726960 | Jan 2008 → Dec 2009 | heroin dependence, opioid abuse | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT00871910 | Oct 2006 → Feb 2010 | non-Hodgkin lymphoma, plasma cell myeloma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00719173 | Aug 2005 → Oct 2010 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00990821 | Jan → Dec 2005 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04398329 | May 2020 → Jul 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 231 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT06357234 | Mar 2025 → Mar 2027 expected | — | IWK Health Centre | Recruiting | No outcome recorded |
| Phase 2 | NCT06462287 | Mar 2024 → Jun 2027 expected | obstructive sleep apnea syndrome | University Hospital, Rouen | Recruiting | No outcome recorded |
| Phase 2 | NCT05202275 | Dec 2020 → Dec 2022 | head and neck squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04470622 | Jul 2020 → Apr 2021 | COVID-19 | Heron Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03683225 | Apr 2019 → Dec 2025 overdue | Parkinson disease | Chase Therapeutics Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03237611 | Oct 2018 → Feb 2021 | chemotherapy-induced toxicity | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT03718039 | Oct 2018 → Jan 2019 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03572829 | Mar 2018 → Jan 2020 | chemotherapy-induced toxicity, head and neck squamous cell carcinoma | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02811055 | Jul 2017 → Dec 2020 | hypertensive disorder, type 2 diabetes mellitus | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 2 | NCT02646020 | Dec 2015 → Oct 2020 | non-small cell lung carcinoma | Sun Yat-sen University | Completed | Met primary |
| Phase 2 | NCT02445872 | Dec 2015 → May 2016 | chemotherapy-induced toxicity, lung cancer | Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT02097823 | Feb 2014 → Feb 2015 | chemotherapy-induced toxicity | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT01963793 | Oct 2013 → Jul 2014 | — | LEO Pharma | Completed | Missed primary |
| Phase 2 | NCT01732458 | Feb 2013 → Sep 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02205164 | Oct 2011 → Aug 2014 | chemotherapy-induced toxicity | Associazione Salentina Angela Serra | Unknown | Missed primary |
| Phase 2 | NCT01334086 | Sep 2011 → Aug 2013 | acute myeloid leukemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01183481 | Jan 2011 → Mar 2013 | — | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01249001 | Oct 2010 → Sep 2016 | — | The Hospital for Sick Children | Terminated | No outcome recorded |
| Phase 2 | NCT01176591 | Sep 2010 → Sep 2013 | alcohol dependence, cocaine dependence | University of Pennsylvania | Completed | Missed primary |
| Phase 2 | NCT01683552 | Sep 2010 → Nov 2011 | — | Campus-Bio-Medico University | Completed | No outcome recorded |
| Phase 2 | NCT01012336 | May 2010 → Oct 2011 | chemotherapy-induced toxicity, ovarian carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01101529 | May 2010 → Dec 2012 | — | Uppsala University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01046461 | Jan 2010 → Mar 2012 | cancer | Hallym University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00970905 | Oct 2009 → Jul 2016 | — | University of Vermont | Completed | Missed primary |
| Phase 2 | NCT00896038 | May 2009 → May 2014 | alcohol dependence, post-traumatic stress disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00600353 | Oct 2007 → Jan 2010 | plasma cell myeloma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01534637 | Aug 2006 → Dec 2009 | malignant tumor of extrahepatic bile duct, pancreas disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00381862 | Jun 2006 → Mar 2008 | colorectal cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00711555 | Nov 2005 → Nov 2008 | — | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00212602 | Aug 2005 → ? | cancer | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00169572 | Feb 2005 → ? | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 337 trials · 8 met primary · 4 missed | ||||||
| Phase 3 | NCT07248280 | Feb → Jul 2026 overdue | — | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 3 | NCT06543966 | Oct 2024 → Mar 2026 overdue | — | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05711823 | Jul → Dec 2024 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06007586 | May 2024 → Jun 2025 | cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer | Sichuan Cancer Hospital and Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT06317064 | Mar → Oct 2024 | primary dysmenorrhea | Lahore Medical Research Center, LLP | Completed | No outcome recorded |
| Phase 3 | NCT06932107 | Feb → May 2024 | — | Qilu Pharmaceutical (Hainan) Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04468646 | Jun → Jul 2020 | — | Prof. Dr. Fridoon Jawad Ahmad | Unknown | No outcome recorded |
| Phase 3 | NCT03808805 | Apr 2019 → Sep 2023 | aquagenic pruritus, myeloproliferative neoplasm | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT02909478 | Sep 2017 → Oct 2019 | chemotherapy-induced toxicity, colorectal cancer | Sun Yat-sen University | Completed | Met primary |
| Phase 3 | NCT02979548 | Nov 2016 → Jun 2018 | acute myeloid leukemia, chemotherapy-induced toxicity | Dr Atul Sharma | Unknown | No outcome recorded |
| Phase 3 | NCT02933099 | Oct 2016 → Apr 2018 | chemotherapy-induced toxicity | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT03674294 | Aug 2015 → Mar 2020 | chemotherapy-induced toxicity, digestive system neoplasm | Sun Yat-sen University | Completed | Met primary |
| Phase 3 | NCT02484911 | May 2015 → Sep 2016 | chemotherapy-induced toxicity | First Affiliated Hospital of Harbin Medical University | Completed | Missed primary |
| Phase 3 | NCT02161991 | Feb 2014 → Feb 2017 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01661335 | Jun 2012 → Jun 2017 | childhood malignant neoplasm | University of Oklahoma | Completed | No outcome recorded |
| Phase 3 | NCT01362530 | Sep 2011 → Mar 2013 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01402024 | Aug 2011 → Jun 2013 | chemotherapy-induced toxicity | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01088022 | Apr 2010 → Mar 2013 | — | Azienda Ospedaliera di Perugia | Unknown | No outcome recorded |
| Phase 3 | NCT00869973 | Sep 2009 → Jul 2012 | — | S. Maria Hospital, Terni | Terminated | Met primary Stop: Enrollment |
| Phase 3 | NCT00869310 | Sep 2009 → May 2012 | — | S. Maria Hospital, Terni | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00952341 | Aug 2009 → Apr 2010 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00572572 | Dec 2007 → Dec 2010 | germ cell tumor | Hoosier Cancer Research Network | Completed | Met primary |
| Phase 3 | NCT00337727 | Jan 2007 → Oct 2008 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00571168 | Jul 2005 → Dec 2010 | plasma cell myeloma | Heidelberg University | Unknown | Met primary |
| Phase 3 | NCT00090246 | May 2004 → Apr 2005 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00080444 | Apr 2004 → Sep 2006 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00090155 | Sep 2003 → Nov 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092196 | Dec 2002 → Dec 2004 | breast neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00048607 | Jul 2002 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00042029 | Jun 2002 → Oct 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00034944 | Jan 2002 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00048594 | Jan 2002 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00035048 | Nov 2001 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00035295 | Nov 2001 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00034983 | Oct 2001 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00035009 | Sep 2001 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00035282 | Sep 2001 → Dec 2003 | major depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 424 trials · 2 met primary · 3 missed | ||||||
| Phase 4 | NCT07639723 | Jul 2026 → Jul 2027 expected | — | Endeavor Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07371728 | Jun 2026 → Jun 2027 expected | disorder of ear | Sir Mortimer B. Davis - Jewish General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06697782 | Jul → Dec 2024 | thyroid cancer | The First Affiliated Hospital of Zhengzhou University | Completed | No outcome recorded |
| Phase 4 | NCT05841849 | Jul 2023 → Jul 2028 expected | breast cancer, chemotherapy-induced toxicity | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05772676 | Dec 2022 → Jan 2023 | obesity disorder | Hospital General Tlahuac | Unknown | No outcome recorded |
| Phase 4 | NCT05189756 | Mar 2022 → Feb 2025 | — | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04649229 | May 2021 → May 2025 | heart failure | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT03435003 | Aug 2017 → Mar 2019 | — | Stony Brook University | Completed | No outcome recorded |
| Phase 4 | NCT02576327 | Oct 2015 → Oct 2017 | — | Jun Zhu | Unknown | No outcome recorded |
| Phase 4 | NCT02347878 | Apr → Oct 2015 | leukemia, lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02357693 | Feb → Aug 2015 | — | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02431286 | Oct 2014 → Dec 2015 | — | Cancer Institute of the State of São Paulo | Unknown | Missed primary |
| Phase 4 | NCT01636947 | Dec 2012 → Aug 2014 | — | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 4 | NCT01897337 | Jun 2012 → Jun 2013 | — | Yonsei University | Completed | Missed primary |
| Phase 4 | NCT01913990 | Sep 2011 → Aug 2017 | — | Ottawa Hospital Research Institute | Unknown | Met primary |
| Phase 4 | NCT01298193 | May 2011 → Mar 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 4 | NCT00977223 | Jun 2009 → Apr 2010 | — | University Hospital, Rouen | Completed | Met primary |
| Phase 4 | NCT00588835 | Mar 2008 → Jan 2010 | neoplasm | Radboud University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00734929 | Sep 2007 → Jun 2009 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT00888329 | Jul 2007 → Oct 2011 | — | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00415103 | Nov 2006 → Sep 2009 | leukemia, lymphoma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00090207 | Jan → Sep 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00092183 | Oct 2002 → Dec 2003 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00429754 | ? → Sep 2008 | — | Radboud University Medical Center | Withdrawn | No outcome recorded |
| Phase not applicable15 trials · 1 met primary | ||||||
| — | NCT04873284 | May → Dec 2021 | chemotherapy-induced toxicity, childhood malignant neoplasm | Shanghai Children's Medical Center | Unknown | Met primary |
| — | NCT04399148 | Jun → Sep 2019 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT02130687 | Jun 2014 → May 2020 | essential hypertension, type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01580423 | Apr 2012 → Mar 2013 | chronic obstructive pulmonary disease | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT01843868 | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01275664 | Jun 2011 → May 2014 | fallopian tube cancer, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +5 | Gynecologic Oncology Group | Terminated | No outcome recorded |
| — | NCT01344304 | Apr 2011 → Nov 2013 | colorectal cancer | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group | Completed | No outcome recorded |
| — | NCT01017809 | Dec 2010 → Dec 2012 | ovarian cancer | NYU Langone Health | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01020903 | Nov 2009 → Nov 2010 | — | Northwell Health | Completed | No outcome recorded |
| — | NCT00999544 | Oct 2009 → Apr 2011 | opioid abuse | Sharon Walsh | Completed | No outcome recorded |
| — | NCT00699894 | Jun → Sep 2008 | — | Northwell Health | Withdrawn | No outcome recorded |
| — | NCT00651755 | Mar 2008 → Sep 2011 | lymphoma | M.D. Anderson Cancer Center | Completed | Mixed |
| — | NCT00499668 | Aug 2007 → Jan 2008 | leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloproliferative neoplasm +1 | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02550119 | Apr 2006 → Apr 2010 | digestive system cancer | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00293384 | Oct 2004 → Jun 2009 | breast cancer, gestational trophoblastic neoplasm, leukemia, myelodysplastic syndrome +5 | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Comparator or background therapy57 trials | ||||||
| Phase 0 | NCT07662200 Comparator | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07817004 Comparator | Sep → Nov 2026 expected | chemotherapy-induced toxicity | Qilu Pharmaceutical (Hainan) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02989467 Comparator | Jan → Nov 2017 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01300988 Comparator | Dec 2010 → Aug 2013 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00428519 Comparator | Jan 2007 → Dec 2009 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT07848984 Background | Oct 2026 → Aug 2028 expected | breast neoplasm | Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07455955 Background | Mar 2026 → Jun 2027 expected | breast cancer | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT03478605 Comparator | May 2018 → May 2019 | chemotherapy-induced toxicity | Blokhin's Russian Cancer Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT02210195 Comparator | Sep 2014 → Dec 2016 | alcohol dependence, cannabis dependence | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01450826 Comparator | Jun 2014 → Apr 2017 | glioma | Katy Peters | Completed | No outcome recorded |
| Phase 2 | NCT01149369 Comparator | Apr 2013 → Aug 2015 | gastroparesis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT01611948 Comparator | May 2011 → Oct 2015 | cannabis dependence | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00954941 Comparator | Nov 2009 → Apr 2013 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00250744 Comparator | Dec 2004 → Sep 2007 | cancer | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| Phase 2/3 | NCT02525848 Comparator | Aug 2015 → Mar 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT06200168 Background | Jan 2024 → Oct 2026 expected | — | Jiuda Zhao | Recruiting | No outcome recorded |
| Phase 3 | NCT04606264 Comparator | May 2023 → Mar 2025 | — | Jennifer Holder-Murray | Completed | No outcome recorded |
| Phase 3 | NCT05346731 Background | Apr 2022 → Mar 2024 | chemotherapy-induced toxicity | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| Phase 3 | NCT04912271 Background | Jun 2021 → Jun 2022 | chemotherapy-induced toxicity | Fudan University | Unknown | Met primary |
| Phase 3 | NCT04437017 Comparator | Feb 2020 → May 2022 | chemotherapy-induced toxicity | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT04075955 Comparator | Apr → Dec 2019 | chemotherapy-induced toxicity | CR-CSSS Champlain-Charles-Le Moyne | Completed | No outcome recorded |
| Phase 3 | NCT03876938 Comparator | Mar 2019 → Aug 2020 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT02939287 Comparator | Sep 2017 → Dec 2021 | — | Rush University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03219710 Background | Jul 2017 → Jul 2019 | chemotherapy-induced toxicity | All India Institute of Medical Sciences | Completed | Met primary |
| Phase 3 | NCT03079219 Background | Mar 2017 → Mar 2021 | breast cancer | CCTU | Completed | No outcome recorded |
| Phase 3 | NCT02336750 Background | Dec 2014 → Dec 2021 | breast cancer | Fudan University | Completed | Met primary |
| Phase 3 | NCT02116530 Background | Aug 2014 → Apr 2015 | cancer of unknown primary site, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 3 | NCT01376297 Comparator | Jul 2011 → Sep 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01536691 Background | Jun 2011 → Nov 2012 | cancer | Hallym University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00619359 Comparator | Feb 2008 → Jun 2009 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00475085 Comparator | Dec 2006 → Dec 2012 | — | Joseph Roscoe | Completed | Mixed |
| Phase 4 | NCT05632224 Comparator | Nov 2022 → Jan 2023 | — | Baskent University | Unknown | No outcome recorded |
| Phase 4 | NCT04013386 Comparator | Jul → Dec 2019 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03831633 Comparator | Sep 2018 → Jul 2019 | — | VIFORFRANCE | Unknown | No outcome recorded |
| Phase 4 | NCT02532634 Background | Aug 2015 → May 2018 | cancer | Kangdong Sacred Heart Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01625455 Comparator | Feb 2012 → Jul 2015 | Sezary syndrome | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01432015 Comparator | Sep 2011 → Mar 2015 | ovarian cancer, uterine cancer | Gynecologic Oncology Associates | Completed | No outcome recorded |
| Phase 4 | NCT02021851 Comparator | Jul 2011 → Jul 2012 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00738621 Comparator | Jul 2008 → Aug 2010 | — | Scott and White Hospital & Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00659945 Comparator | Jun 2008 → Nov 2009 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT01474915 Comparator | Jun 2007 → Dec 2012 | — | Sergio Bergese | Completed | No outcome recorded |
| Phase 4 | NCT00781768 Comparator | Aug 2003 → Oct 2008 | — | Loyola University | Completed | No outcome recorded |
| — | NCT06080880 Background | Dec 2023 → Nov 2025 overdue | chemotherapy-induced toxicity | Hubei Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02226601 Comparator | Oct 2014 → Oct 2016 | cognitive disorder | University of Arizona | Unknown | No outcome recorded |
| — | NCT02597907 Background | Jul 2014 → May 2015 | — | Kyungpook National University Hospital | Completed | Met primary |
| — | NCT01393288 Comparator | Nov 2013 → Nov 2014 | — | University of California, San Francisco | Withdrawn | No outcome recorded |
| — | NCT01854177 Comparator | Jul → Nov 2013 | chronic obstructive pulmonary disease | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT01186029 Comparator | Sep 2011 | — | University of Nebraska | Withdrawn | No outcome recorded |
| — | NCT01640340 Background | Jan → Aug 2011 | cancer | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT00956215 Comparator | May 2010 → Jan 2012 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT01440673 Comparator | Mar → Sep 2010 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| — | NCT00835965 Comparator | Feb → Dec 2009 | — | Main Line Health | Unknown | No outcome recorded |
| — | NCT00659737 Comparator | Apr 2008 → Mar 2010 | — | Drexel University College of Medicine | Completed | No outcome recorded |
| — | NCT00717054 Comparator | Feb 2008 → Mar 2010 | — | Drexel University | Completed | No outcome recorded |
| — | NCT00736073 Comparator | Aug 2007 → Aug 2010 | pancreatitis | Duke University | Completed | No outcome recorded |
| — | NCT00248547 Comparator | May 2004 → Jan 2009 | cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ |
| 2024-09-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL |
| 2022-09-16 | Heron Therapeutics | Regulatory Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) herontx.com ↗
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults. |
| 2021-11-18 | Heron Therapeutics | Regulatory Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA herontx.com ↗
today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion |
| 2019-10-22 | Heron Therapeutics | Regulatory Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC) herontx.com ↗
SAN DIEGO, Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion for intravenous (IV) use. |
| 2019-08-15 | Upsher-Smith Laboratories | Regulatory Sawai Receives Approvals for Two Generic Drugs with Five Strengths upsher-smith.com ↗
Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for two generic drugs with five strengths. |
| 2017-11-09 | Heron Therapeutics | Regulatory Heron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) herontx.com ↗
Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved CINVANTI™ (aprepitant) injectable emulsion, for intravenous infusion. |
| 2015-09-02 | Merck Sharp & Dohme LLC | Regulatory FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents merck.com ↗
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND ® (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. |
| 2014-06-30 | Merck Sharp & Dohme LLC | Results Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy merck.com ↗
In this large pediatric study, adding EMEND to a standard regimen for prevention of CINV resulted in significant reduction of emetic events. |
All press releases naming this drug 17 releases
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 186 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aprepitant | “Aprepitant capsules may be given to patients from 3-5 days fosaprepitant dimeglumine (Injection 115mg, prodrug form of aprepitant) may be substituted for oral drug in case of...” NCT04468646 ↗181“Day 1: Aprepitant 125mg QD (once daily); Ondansetron 8mg BD (twice daily); Dexamethasone 12mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before...” NCT07455955 ↗ “Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles.” NCT01843868 ↗ “Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg” NCT06200168 ↗ “Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.” NCT00871910 ↗ “the test product QLM2010 (18 mL: aprepitant 130 mg and palonosetron hydrochloride 0.25 mg, manufactured by Qilu Pharmaceutical \[Hainan\] Co., Ltd.)” NCT07817004 ↗ “Aprepitant (EMEND®) is a selective high-affinity receptor antagonist of human substance P/neurokinin-1 (NK1)” NCT00571168 ↗ “NK-1 receptor antagonists may include fosrolapitant, aprepitant, or fosaprepitant.” NCT07848984 ↗ “HTX-034 (bupivacaine/aprepitant/meloxicam) fixed dose: 21.7 mg/4.3 mg/0.6 mg” NCT04398329 ↗ “oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)” NCT03831633 ↗ “aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone” NCT01536691 ↗ |
| Known as | APONVIE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1471 ↗ |
| Known as | APR | “the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy.” PMID 15837996 ↗ Apr 2005 |
| Known as | APREPITANT (MK-0869) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1471 ↗ |
| Known as | aprepitant(emend) | “Aprepitant = Emend” NCT01661335 ↗1“aprepitant(emend)” NCT02532634 ↗ |
| Known as | CINVANTI | “Reference Product 1 (aprepitant injection CINVANTI®, 18 mL: 130 mg, manufactured by Alcami Carolinas Corp.)” NCT07817004 ↗ |
| Known as | EMEND | “The purpose of this study is to evaluate the effectiveness of Aprepitant, also known as Emend, in reducing post-operative nausea and vomiting in morbidly obese patients.” NCT00956215 ↗7“Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving” NCT01176591 ↗ “EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.” NCT06931119 ↗ “Aprepitant (EMEND®) is a selective high-affinity receptor antagonist of human substance P/neurokinin-1 (NK1)” NCT00571168 ↗ “Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals” NCT00428519 ↗ “newly approved drug known as aprepitant (MK-869, Emend)” NCT00781768 ↗ “Aprepitant (Emend®) 375 mg daily for 14 days” NCT01300988 ↗ “Efficacy of Aprepitant (Emend®) in Children” NCT01661335 ↗ |
| Known as | Emend - aprepitant | “Emend - aprepitant” NCT01536691 ↗1“Emend=aprepitant” NCT00738621 ↗ |
| Known as | L-754,030 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1471 ↗ |
| Known as | MK-0869, Emend | “MK-0869, Emend®” NCT01362530 ↗ |
| Known as | MK-869 | “Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide” NCT00293384 ↗1“newly approved drug known as aprepitant (MK-869, Emend)” NCT00781768 ↗ |
| Known as | MK0869 | “Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting” NCT00080444 ↗10“MK0869, aprepitant / Duration of Treatment: 3 days” NCT00092183 ↗ “MK0869, aprepitant / Duration of Treatment: 3 days” NCT00090207 ↗ “MK0869, aprepitant / Duration of Treatment: 3 days” NCT00092196 ↗ “Aprepitant (MK-0869)” NCT00952341 ↗ “MK0869, aprepitant” NCT00090155 ↗ “MK0869, aprepitant” NCT00035009 ↗ “MK0869, aprepitant” NCT00034944 ↗ “MK0869, aprepitant” NCT00090246 ↗ |
| Known as | NSC-748825 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1471 ↗ |
| Known as | ONO-7436 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00212602 ↗ |
| Known as | QLG2174 | “A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of...” NCT06932107 ↗ |
| Action | Inhibit | “neurokinin(1) receptor) antagonist” PMID 16248986 ↗ Oct 20051“Neurokinin 1 receptor antagonist” CHEMBL1471 ↗ |
| Modality | Other / unclassified | “Aprepitant is a licensed treatment for nausea and vomiting” NCT04912271 ↗ |
| Route | Oral | “aprepitant 125 mg orally (PO)” NCT00080444 ↗ |
| Target | CYP3A4 | “Aprepitant acts initially as a moderate inhibitor of CYP3A4” NCT00588835 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL1471 ↗ |